10-Q: Myomo Inc. Reports Strong Q1 Revenue Growth Driven by Direct Billing Channel

Myomo Inc. reports a significant increase in first-quarter revenue, driven by growth in its direct billing channel and higher average selling prices, despite ongoing net losses.

Summary

• Myomo Inc. reported a net loss of $3.465 million for the three months ended March 31, 2025, compared to a net loss of $3.836 million for the same period in 2024.
• The company's revenue increased by 162% to $9.832 million in Q1 2025 from $3.754 million in Q1 2024, primarily driven by higher direct billing revenues.
• Gross margin improved to 67.2% in Q1 2025 from 61.2% in Q1 2024, due to higher average selling prices and greater absorption of fixed costs.
• Operating expenses increased by 64% to $10.130 million in Q1 2025 from $6.188 million in Q1 2024, driven by higher R&D, selling, clinical, and marketing expenses.
• The company's cash and cash equivalents decreased to $19.794 million as of March 31, 2025, from $24.372 million as of December 31, 2024.
• Myomo believes its available cash, cash equivalents, and short-term investments will fund its operations for at least the next twelve months.
• The company is focused on growing revenues in its direct billing and O&P channels, which involves increasing advertising spending and adding headcount.
• Myomo has a revolving line of credit with Silicon Valley Bank, with approximately $216,600 available as of March 31, 2025.
• A term loan facility of up to $3.0 million is available until February 28, 2026, but remains undrawn as of the issuance date of these financial statements.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While revenue growth is strong and gross margins are improving, the company continues to experience net losses and has identified a material weakness in internal controls. The future outlook is cautiously optimistic, dependent on successful execution of growth strategies and favorable reimbursement policies.

Positives

• Significant revenue growth driven by the direct billing channel.
• Improved gross margin due to higher average selling prices and better cost absorption.
• Successful completion of a public offering, providing additional capital.
• Availability of a term loan facility to further support operations.
• CMS final payment determinations for the HCPCS codes describing MyoPro products which became effective on April 1, 2024.
• CMS fees were subsequently updated to approximately $34,300 for the Motion W and approximately $67,500 for the Motion G, effective January 1, 2025.

Negatives

• Continued net losses and negative cash flows from operations.
• Increased operating expenses due to investments in R&D, selling, clinical, and marketing activities.
• Dependence on third-party payer reimbursement, including Medicare and Medicaid.
• Material weakness identified in internal control over financial reporting.
• Decreased lead generation for the first half of the first quarter and a higher cost per pipeline add in the first quarter due to a change to a social media advertising company algorithm.

Risks

• Potential restrictions or retraction of coverage requirements by CMS and Medicare Advantage plans.
• Changes in direct-to-consumer advertising methods impacting lead generation.
• Significant political, trade, and regulatory developments affecting international sales.
• Dependence on reimbursement of products by insurance companies and government-controlled health care plans.
• The company may not be able to obtain third-party payer reimbursement, including reimbursement by Medicare, for our products.

Future Outlook

Myomo plans to invest in increasing demand and capacity to support its direct billing channel while also growing revenues in the U.S. O&P channel, expecting negative cash flows for at least the first three quarters of 2025, with a goal to return to positive cash flow from operations on a quarterly basis by the fourth quarter 2025.

Management Comments

• Management's operating plans are primarily focused on growing revenues in its direct billing channel, while working to grow revenues in its O&P channel.
• These plans include increasing advertising spending and adding headcount to support growth in its clinical, reimbursement, and manufacturing capacity in order to serve a higher volume of patients in 2025.

Industry Context

Myomo operates in the wearable medical robotics industry, focusing on myoelectric orthotics. The company's performance is influenced by factors such as reimbursement policies, technological advancements, and competition from other medical device companies.

Comparison to Industry Standards

• It is difficult to compare Myomo directly to industry standards as there are few publicly traded companies that focus exclusively on myoelectric orthotics.
• Companies like Ekso Bionics and ReWalk Robotics are involved in exoskeletons, but their focus is broader than upper limb orthotics.
• Myomo's gross margin of 67.2% is relatively strong for a medical device company, suggesting efficient manufacturing and pricing strategies.
• However, the continued net losses indicate that the company needs to scale its operations and reduce operating expenses to achieve profitability.

Stakeholder Impact

• Shareholders: The strong revenue growth is positive, but continued losses and the material weakness in internal controls are concerning.
• Employees: Increased headcount suggests job security and potential career growth, but the company's financial stability depends on successful execution of its plans.
• Customers: Continued product development and improved reimbursement could lead to better access to Myomo's devices.
• Suppliers: Increased production volume could lead to higher demand for components and materials.
• Creditors: Myomo's ability to repay its debts depends on its ability to achieve profitability and positive cash flow.

Next Steps

• Increase advertising spending and add headcount to support growth in the direct billing channel.
• Increase R&D spending to accelerate the completion of sustaining and new product development activities.
• Fund systems and headcount to support growth in the O&P channel.
• Remediate the material weakness in internal control over financial reporting.

Key Dates

Keywords

Myomo, revenue, direct billing, MyoPro, orthotics, Medicare, reimbursement, financial results, Q1 2025